title: Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer.
abstract: Women with breast cancer face many challenges when considering fertility preservation. Delayed referral results in the limitation of fertility preservation options because most established methods, such as embryo and oocyte cryopreservation, require several weeks to complete. Women with BRCA mutations, on the other hand, may be more aware of fertility issues and motivated to see fertility preservation specialists earlier. Fear of exposure to estrogen limits access to fertility preservation via embryo or oocyte cryopreservation; however, the use of aromatase inhibitors as ovarian stimulants reduces such concern. Ovarian cryopreservation can be used when there is insufficient time to perform ovarian stimulation because this technique does not require hormonal stimulation, but there are safety concerns both in women with BRCA mutations and in patients with hormone receptor-positive disease as well. There does not seem to be a proven ovarian suppression strategy to preserve fertility in women with breast cancer. Pregnancy appears to be safe for breast cancer survivors but studies specific for women with BRCA mutations are lacking. Women with BRCA mutations may elect to use preimplantation genetic diagnosis during in vitro fertilization to avoid transmitting the mutation, but there may be psychosocial difficulties in entertaining this option. Overall, the last decade has brought many options for women with breast cancer considering fertility preservation, but numerous challenges remain. The presence of BRCA mutations further contributes to these challenges.
authors.affiliation: Institute for Fertility Preservation, Rye, New York 10580, USA. koktay@fertilitypreservation.org
authors.forename: Kenny A
authors.initials: KA
authors.lastname: Rodriguez-Wallberg
authors.forename: Kutluk
authors.initials: K
authors.lastname: Oktay
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D015925:Cryopreservation; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D059247:Fertility Preservation; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D007247:Infertility, Female / Q000139:chemically induced / Q000209:etiology; D054315:Oocyte Retrieval; D010062:Ovulation Induction; D011247:Pregnancy; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D066246:ErbB Receptors